Best of ACTHIV: Mental Health and Substance Use in PWH—A Review of Diagnosis and Treatment for the HIV Care Team
Presentation date:May 6, 2022
This presentation was part of the 16th Annual American Conference for the Treatment of HIV (ACTHIV 2022), which held May 5-7, 2022. The conference was supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck, Theratechnologies, and ViiV Healthcare.
The presentation on which this activity is based was selected by ACTHIV 2022 conference attendees and the conference planning committee as being among the best sessions of the conference. The goal of this activity is to help members of the frontline HIV care team to be better able to:
- Identify the most common mental health and substance use disorders among people with HIV
- List screening tools for these disorders which can be integrated into practice
- Identify barriers and facilitators to treatment for mental health and substance use disorders
- Explain the opportunities an integrated care model offers for improving mental health and substance use disorder treatment in people with HIV
To view additional Best of ACTHIV 2022 sessions, visit https://acthiv.org/online-learning/
Alexandra Canetti, MD
Assistant Professor of Psychiatry
Columbia University Medical Center
In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses
American Academy of CME, Inc., designates this educational activity for 0.5 ANCC contact hours.(0.1 Pharmacotherapeutic Contact Hours)
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 15, 2023. PAs should only claim credit commensurate with the extent of their participation.
Other members of the care team will receive a certificate of participation.
This activity has been designed to meet the educational needs of the HIV care team, including physicians (both specialists and primary care/family medicine), nurses, nurse practitioners, physician assistants, and pharmacists who are in practice but are newer to HIV medicine or who are in training. Other healthcare providers may also participate.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Faculty Educator Disclosures:
Faculty Disclosure: Alexandra Canetti, MD: has no relevant financial relationships to disclose.
The following individuals have no relevant financial relationships to disclose:
Beatrice Aladin, MD, MPA; Jillian Baron, MD, MPH; John T Brooks, MD; Jose Castillo-Mancilla, MD; Lisa Catalli, MSN, NP-C; Jonathan Colasanti, MD, MSPH; Sherrillyn Crooks, PA-C; Christopher Evans, MD; Courtney V Fletcher, PharmD; Donna Futterman, MD; Rajesh Gandhi, MD; Mary Glenshaw, PhD, MPH, OTR/L; Jose Gutierrez, PhD, MSN, FNP-BC; Tomasz Jodlowski, PharmD; John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Jennifer Kay-Berene Klein, MSN; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Amber McCracken; Lorenzo McFarland, DHA, MPH, MSW, PMP; Paul Miniter, MS; Edward Moylan, RP; Asa Radix, MD, PhD, MPH; Dianne Rausch, PhD; Aaron Richterman, MD MPH; Jeri (Jieri) Sumitani, MMSc, PA-C; Pablo Tebas, MD; Ronald Dean Wilcox MD; Darcy Wooten, MD, MS
The following individuals have relevant financial relationships to disclose:
Dawn Averitt, BIS: Advisory Board/Consultant – Merck, Gilead Sciences, ViiV Healthcare
Roger Bedimo, MD, MS: Advisory Board/Consultant – Merck, ViiV Healthcare, Theratechnologies*
Eric Daar, MD: Advisory Board/Consultant – Merck, Gilead Sciences, ViiV Healthcare; Grant/Research Support – Gilead Sciences, ViiV Healthcare
Carlos del Rio, MD: Advisory Board/Consultant: Resverolix, Sanofi-Pasteur*
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board/Consultant – ViiV Healthcare; Grant/Research Support – ViiV Healthcare; Speakers Bureau – Gilead Sciences, ViiV Healthcare
Nina Kim, MD, MSc: Grant/Research Support – Gilead Sciences
Igho Ofotokun, MD, MSc: Grant/Research Support – Merck
Tonia Poteat, PhD, MPH, PA-C: Advisory Board/Consultant – Merck, ViiV Healthcare
Jennifer Price, MD, PhD: Advisory Board/Consultant – Theratechnologies, Gilead Sciences, Merck; Grant/Research Support – Gilead Sciences, Merck; Speaker’s Bureau – Gilead Sciences
Jason Schafer, PharmD, MPH: Advisory Board/Consultant – Merck, ViiV Healthcare; Grant/Research Support – Merck, Gilead Sciences*
Renslow Sherer MD: Grant/Research Support – Gilead Sciences
William R Short, MD, MPH, FIDSA: Advisory Board/Consultant – Gilead Sciences, ViiV Healthcare; Speaker’s Bureau – ViiV Healthcare, Janssen
Babaafemi Taiwo, MBBS: Advisory Board/Consultant – Gilead Sciences, Merck, ViiV Healthcare, Janssen
Melanie Thompson, MD: Grant/Research Support – Cepheid Inc, Cytodyn Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck, ViiV Healthcare
Andrea Weddle, MSW: Policy Consultation: Merck
Susan Weiss, FNP-BC, MSN, AAHIVS: Advisory Board* – Gilead Sciences, Merck, ViiV Healthcare, Janssen; Speaker’s Bureau* – Gilead Sciences, ViiV Healthcare, Janssen
*Indicates relationship has ended
This activity will not review off-label or investigational information.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or its ACTHIV Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Instructions on How to Receive Credit
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME/CE credit for your participation, please complete the post-assessment and program evaluation. Your certificate will be available for printing immediately.
Privacy and Contact
This program should be viewed at a resolution of 1024 x 768 or higher using current versions of Microsoft Internet Explorer, Firefox, Chrome or Safari. A high-speed Internet connection is recommended.
© 2022. This accredited continuing education activity is held as copyrighted © by American Academy of CME. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).